Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02678351 · ClinicalTrials.gov registry record · Phase 2
68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery
A Phase 2 study, sponsored by Andrei Iagaru.
- Completed
- Registry status
- Phase 2
- Development phase
- 74
- Enrollment target
NCT02678351 is a Phase 2 study that has completed, run by Andrei Iagaru. The registered enrollment target is 74 participants.
The verdict
NCT02678351, a Phase 2 study, has completed, sponsored by Andrei Iagaru.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 74 participants
- Enrollment target
Study Summary
This phase 2-3 trial studies the utility of 68-gallium (68Ga)-prostate-specific membrane antigen 11 (PSMA-11) positron emission tomography/magnetic resonance imaging (PET/MRI) to find tumors in patients with prostate cancer who are undergoing resection surgery for prostate cancer that is prognostically expected to spread quickly (intermediate-risk) or is likely to come back or spread (high-risk). Diagnostic procedures, such as PET/MRI, may help find and diagnose prostate cancer, and reveal out how far the disease has spread. Radioactive drugs, such as 68Ga-PSMA-11, may bind to tumor cells that have specific receptors, and may allow doctors to see smaller tumors than the standard of care contrast-enhanced computed tomography (CT) or MRI scan.
Interventions
- PROCEDURE Magnetic resonance imaging (MRI)
- DRUG 68Ga-PSMA-11
- PROCEDURE Positron Emission Tomography (PET)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2016-04-18 |
| Est. Completion | 2021-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02678351
The ClinicalTrials.gov registry entry for NCT02678351 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Andrei Iagaru, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Magnetic resonance imaging (MRI) is the first listed.
NCT02678351 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02678351 about?
NCT02678351 is a clinical study titled "68Ga-PSMA-11 PET/MRI in Finding Tumors in Patients With Intermediate or High-Risk Prostate Cancer Undergoing Surgery". This phase 2-3 trial studies the utility of 68-gallium (68Ga)-prostate-specific membrane antigen 11 (PSMA-11) positron emission tomography/magnetic resonance imaging (PET/MRI) to find tumors in patients with prostate cancer who are undergoing resection surgery for prostate cancer that is prognostica...
What is the current status of trial NCT02678351?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 74 participants. The study started on 2016-04-18. Estimated completion is 2021-12.
What interventions are being tested in trial NCT02678351?
The interventions under investigation include: Magnetic resonance imaging (MRI) (PROCEDURE), 68Ga-PSMA-11 (DRUG), Positron Emission Tomography (PET) (PROCEDURE).
Who is sponsoring clinical trial NCT02678351?
This trial is sponsored by Andrei Iagaru, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.